We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Drops Req’s for Testing Untreated Patients in Hemophilia
EMA Drops Req’s for Testing Untreated Patients in Hemophilia
The European Medicines Agency revised two guidelines on the development and labeling of factor VIII products used to treat hemophilia A, removing requirements for sponsors to conduct clinical trials in previously untreated patients.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor